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Abstract: Mediastinal and hilar lymph node involvement are rarely
reported in the literature concerning pulmonary metastasectomy.
The first problem is to determine with accuracy the incidence and
location of thoracic lymph node involvement in patients with lung
metastases. Determination of the impact on survival of this type of
lymphatic spread may contribute to assessing whether metastatic
nodal disease identified preoperatively is an absolute contraindica-
tion to metastasectomy. Systematic mediastinal lymph node dissec-
tion has revealed a statistically significant difference in survival
between patients with lymph node involvement and those without
lymph node metastases. Videomediastinoscopy to identify involved
mediastinal lymph nodes can be safely performed and may have a
role in a more accurate staging of the metastatic disease. The authors
conclude that attention should be paid to ensuring that we do not
operate on patients in whom we will leave behind diseases that we
cannot reach. The discovery of mediastinal lymph node involvement
may also influence decisions with respect to postresection adjuvant
therapy.
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Mediastinal and hilar lymph node involvement had infre-quently been examined in the literature concerning
pulmonary metastasectomy before 2000. In publications
since 2000, among the prognostic factors considered, metas-
tasis from pulmonary metastases to the pulmonary lymphatic
drainage has increasingly been considered. The true inci-
dence, the pattern of lymph node involvement, the clinical
significance, and the pathologic and oncologic interpretation
now need to be clarified. Consequently, to obtain information
and gauge opinion in this respect, it is necessary to conduct
the appropriate examination of clinical reports in which, apart
from any other prognostic factors, the presence and signifi-
cance of nodal involvement have been analyzed.
WHAT IS THE TRUE INCIDENCE OF THORACIC
LYMPH NODE INVOLVEMENT?
The first problem is to determine the incidence of
positive thoracic lymph nodes in patients with lung metasta-
ses. In the International Registry of Lung Metastases between
1991 and 1995 of 5206 patients, 4572 (88%) underwent a
complete surgical resection of the metastases.1 Data are
available from this source on the incidence of lymph node
involvement in a large number of patients. The primary tumor
was epithelial in 2660 cases, sarcoma in 2173, germ cell in
363, and melanoma in 328. Metastases to hilar or mediastinal
nodes were found in 5% of patients overall (239 cases),
corresponding to 11% in germ-cell tumors, 8% of melano-
mas, 6% of epithelial metastases, and only 2% of sarcomas.
This is the largest data set available nevertheless, there are
some difficulties in interpreting these results:
1. There were 18 participating centers from nine different
countries.
2. There was no uniform use of radiologic techniques or
consistent preoperative evaluation to categorize hilar or
mediastinal metastases.
3. Criteria for performing preoperative mediastinoscopy
varied.
4. The practice of intraoperative nodal dissection also
varied and was performed in less than 9% of the
patients. In general, only suspicious lymph nodes were
removed.
It follows from the means of collection of data, the
variations in practice, and the low rate of nodal dissection,
that this incidence rate might be an underestimate, a suppo-
sition supported by analysis of subsequently published case
series specifically addressing this particular question among
groups of patients in which there was a policy of nodal
sampling or systematic dissection. More recent studies, par-
ticularly, in epithelial tumors, therefore permit better deter-
mination of the incidence of thoracic lymph node and its
repercussion in long-term survival.
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We have extracted data on the incidence of mediastinal
nodal involvement in six publications from 2001 to 2007
(Table 1), which shows a weighted average of 22%. These are
of course already selected patients under consideration for
having pulmonary metastasectomy, so it is still likely to be an
underestimate of the true pathologic potential for metastases
to themselves metastasize. It seems likely that because these
pulmonary metastases come from tumors that have ipso facto
demonstrated their metastatic potential that the metastases
will in turn behave like other invasive lung tumors and seed
the draining lymph nodes.
Loehe et al.2 studied prospectively 63 patients with
lung metastases, most of them from primary epithelial ma-
lignancies, who underwent 71 resections, and systematic
mediastinal lymph node dissection. In nine patients (14%), at
least one mediastinal lymph node with malignant cells was
found. In these patients selected for metastasectomy, none of
the preoperative computed tomography chest scans reported
suspicion of malignant involvement of mediastinal nodes.
Saito et al.3 reported data on 165 patients with colorectal
carcinoma, who underwent pulmonary metastasectomy from
1990 to 2000 at eight institutions. Hilar or mediastinal lymph
nodes dissection or sampling in 138 patients revealed metas-
tases in 20 patients (14%). In 2004, Ercan et al.4 published the
experience gained from the study in 883 patients who under-
went pulmonary metastasectomy. Among them, only 70 pa-
tients (8%), treated from 1985 to 1999, had concomitant
complete lymphadenectomy. Lymph node metastases were
found in 20 of the 70 patients (29%; N1 in 9, mediastinal N2
in 8, and both in 3).
More recently, several other studies make reference to
the location and the incidence of nodal metastasis.
Pfannschmidt5 reported on 245 patients who underwent pul-
monary resection of lung metastases from colorectal carci-
noma, sarcoma, and renal cell carcinoma. Systematic medi-
astinal and hilar lymph node dissection revealed lymph node
involvement in 80 patients (45 pulmonary and hilar metasta-
ses; 22 pulmonary, hilar, and mediastinal metastases; and 13
only mediastinal involvement without pulmonary and hilar
spread). Welter et al.,6 among 169 patients operated for
pulmonary metastases of colorectal cancer, found 28 patients
with thoracic nodal spread (10 intrapulmonary, 12 hilar, and
6 mediastinal). Menon et al. found clinically unsuspected
nodal involvement in 6 of 57 at mediastinoscopy and recom-
mend that this investigation should be performed in all
patients.
It is said of sarcoma that because this cancer has a low
propensity for lymphatic metastasis, local control in the lung
can be achieved by repeated surgery. In Pfannschmidt’s
series, among 58 patients with 10 different histologic cate-
gories, all clearly identified as sarcoma and 19% (11 patients)
had nodal metastases.
Because these data based on existing practice show that
for one in five patients, pulmonary metastases have already
metastasized to the lymph nodes draining the lung, this may
be presented as an argument for prompt removal of all
pulmonary metastases (in which the lung is the only known
site of metastatic disease) to preempt spread. This view is
expressed by Pfannschmidt, “If pulmonary and lymph node
metastases are clinically important because they serve as a
source of ongoing disease dissemination, early removal of
such lesions may interrupt the cascade of metastatic cells
derived from metastatic sites. Thus, surgery may be an
important form of systemic therapy.”5 However, we know
that longer survival after metastasectomy is consistently as-
sociated with longer intervals between resection of the pri-
mary cancer and metastasectomy. Therefore, it is open to
question whether the hasty removal to prevent spread is going
to be an overall effective treatment. The presence of meta-
static disease in the nodes draining the lung indicates further
dissemination and it may be that metastasectomy is unlikely
to alter the course of the disease.7 Therefore, what we need to
determine is whether the presence of nodal disease is a
contraindication to metastasectomy. We address this question
next.
WHAT IS THE IMPACT ON SURVIVAL FOR
PATIENTS IN WHOM PULMONARY
METASTASES HAVE THEMSELVES
METASTASIZED TO LYMPH NODES?
There have been many retrospective studies of sur-
gical treatment for pulmonary metastases from colorectal
cancer in which prognostic factors have been carefully
investigated. In the report by Kondo et al.8 in which data
from 10 reported series are reviewed, regional lymph node
involvement emerged as an important prognostic factor, in
addition to the number of pulmonary metastases and serum
carcinoembryonic antigen level. We have summarized data
from five articles in Table 2 which provide data on the
difference in prognosis with and without thoracic lym-
phatic involvement.2–6
TABLE 1. Incidence of Thoracic Lymph Nodes in Patients with Lung Metastases
Publication Era Primary Patients
Nodal
Spread Percent
Loehe et al.2 1996–1998 Mixed 63 9 14
Saito et al.3 1990–2000 Colorectal 138 20 14
Ercan et al.4 1985–1999 Mixed 70 20 29
Pfannschmidt5 1996–2001 Mixed 245 80 33
Welter et al.6 1993–2003 Colorectal 169 28 17
Menon et al.9 2002–2005 Mixed 57 6 11
Weighted average 22
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To highlight two recent examples, among 245 patients
who underwent pulmonary metastasectomy and systematic
mediastinal lymph node dissection, Pfannschmidt5 showed a
statistically significant difference in survival between patients
with lymph node involvement and those without lymph node
metastases (median survival 63.9 months; with N1 disease,
32.7 months; with N1  N2 disease, 20.6 months). Welter et
al.6 studied the prognostic impact of unexpected lymph node
metastases in patients undergoing resection of pulmonary
metastases from colorectal cancer and specified the influence
of pulmonary and mediastinal nodal involvement. The sur-
vival difference between pulmonary (86 months) and hilar/
mediastinal metastases (25 and 35 months) was statistically
significant. Five-year survival with pulmonary, hilar, and
mediastinal metastases was 78.5, 0, and 0%, respectively.
Given these differences that are large and consistent in
Table 2, a clear case can be made for better preoperative
evaluation. In the study by Menon et al.,9 they reported that
videomediastinoscopy identified involved mediastinal lymph
nodes in 6 of 57 patients undergoing pulmonary metastasec-
tomy, most of them from colorectal cancer.
The hidden nature of nodal involvement and its pow-
erful effect on prognosis probably applies to all cancer types
in which pulmonary metastasectomy is considered. Khan et
al.10 have studied the role of surgery in pulmonary metastases
of endocrine origin. None of the surgical patients had any
radiographic evidence of mediastinal disease preoperatively.
Mediastinoscopy was not performed in any patient. At the
time of surgery, mediastinal lymph node sampling was per-
formed. Patients without mediastinal nodal involvement and
those with a longer duration before development of pulmo-
nary metastases had the best prognosis.
WHAT IS CURRENT PRACTICE OF LYMPH
NODE ASSESSMENT AND DISSECTION?
In a recent European Society of Thoracic Surgeons
survey,11 the presence of clinically positive lymphadenopathy
is believed to be a relative contraindication to pulmonary
metastasectomy by 64%, whereas biopsy proven or patholog-
ically positive mediastinal nodes constitute an absolute (64%)
or relative (32%) contraindication for most of the observed
population. Nevertheless, a systematic assessment of medi-
astinal nodes before lung metastasectomy is apparently an
uncommon practice. Most of the responders rarely (43.8%) or
never (24%) perform mediastinoscopy, whereas another
28.8% state that this is done only “sometimes,” and usually
because of increased suspicion by preoperative imaging tests.
Only 3.4% of responders consistently verified mediastinal
lymph nodes by mediastinoscopy (2% usually and 1.4%
always) before selecting a patient for surgical resection. At
the time of pulmonary metastasectomy, roughly half (55.5%)
of the responding surgeons perform mediastinal lymph nodal
sampling, whereas 13% perform a complete mediastinal
lymphadenectomy. One in three surgeons (32.2%) performs
no lymph node biopsy whatsoever.
After this analysis, we agree with the editorial comment
of Treasure7 in relation to this problem: “If the benefit we
offer is that we cure some and that these are the only ones
who benefit, then we should pay great attention to ensuring
that we do not operate on patients in whom we will leave
behind disease we cannot reach, because at present there may
be 10% of patients who could be spared this unavailing lung
resection if we were to stage the mediastinum. We should pay
great attention to ensuring that we do not operate in patients
in whom we will leave behind disease we cannot reach.”
CONCLUSIONS
1. The incidence of lymphatic spread from the pulmonary
metastases to the usual lymphatic drainage of the lung is
common, probably more common than generally rec-
ognized. Patients are highly selected for metastasec-
tomy so the reports based on surgical series will be an
underestimate but of patients with unsuspected nodal
involvement, and recurrent cancer clinically only in-
volving the lung, more than a fifth have thoracic nodal
disease. Furthermore, this seems to occur irrespective of
the type of primary cancer.
2. Patients who have mediastinal nodal disease have a
much worse survival than those whose nodes are clear.
This has been clearly shown and is not surprising.
3. We concur with the views of several authors of these
reports, and with Treasure’s editorial, that best practice
would be to exclude, as far as possible, patients with
thoracic nodal involvement from pulmonary metastasec-






Positive Survival5 yr 10 yr
Loehe et al.2 1991–1998 53a 36a 26a 9 0.5 yr
Saito et al.3 1990–2000 118 49 46 20 0.5 yr
Ercan et al.4 1985–1999 50 48 20 5 yr (10%)
Pfannschmidt5 1996–2001 165 45a 80 —b
Welter et al.6 1993–2003 169 42 28 19%
Best estimates of comparable survival from published series in which nodal status is reported. Survival is variously reported as 3, 5, or
10 yr average or median survival. When the data are not provided in this form, best estimates have been obtained from graphical displays
for purposes of comparison.
a Editor’s best estimates from published data available including graphs.
b Data are subdivided according to N1, N2, N1  N2.
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tomy with intent to cure. At present, mediastinoscopy
seems to be the most effective way of achieving this.
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